Business
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
Med Tech segment delivers fifth consecutive quarter of double-digit growth Strong adjusted EBITDA; and positive cash flow Three regulatory milestones support
About this update from Angiodynamics, Inc.
[{"type":"text","content":"\n\nMed Tech segment delivers fifth consecutive quarter of double-digit growth\n\n\n\nStrong adjusted EBITDA; and positive cash flow\n\n\n\nThree regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac 510(k) clearance, PAVE and APEX-Return IDE approvals\n\n\n\nRaised full year FY 2026 guidance for net sales and Adjusted EBITDA\n\n\n\nJim Clemmer to retire during fiscal year 2027 as President and CEO upon appointment of successor; Board initiates comprehensive CEO search\n\n\n\n LATHAM, N.Y.--(BUSINESS WIRE)--\nAngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025.\n\n\nFiscal Year 2026 Second Quarter Highlights\n\n\n\n\n \n\n\n\n\n\n \n\nQuarter Ended\nNovember 30, 2025\n\n\n\n\n\n\n \n\n\n\n\n\n\nPro Forma* YoY Growth\n\n\n\n\n\n\n\n\nNet Sales\n\n\n\n\n\n \n\n$79.4 million\n\n\n\n\n\n\n \n\n\n\n\n\n\n8.8%\n\n\n\n\n\n\n\n\nMed Tech Net Sales\n\n\n\n\n\n \n\n$35.7 million\n\n\n\n\n\n\n \n\n\n\n\n\n\n13.0%\n\n\n\n\n\n\n\n\nMed Device Net Sales\n\n\n\n\n\n \n\n$43.8 million\n\n\n\n\n\n\n \n\n\n\n\n\n\n5.6%\n\n\n\n\n\n\n\n\nGAAP gross margin of 56.4%\n\n\n\nGAAP loss per share of $0.15\n\n\n\nAdjusted loss per share of $0.00\n\n\n\nAdjusted EBITDA of $5.9 million\n\n\n\nEnded fiscal 2026 second quarter with $41.6 million in cash and cash equivalents, ahead of the Company’s expectations, continues to expect to be cash flow positive for the full year FY 2026\n\n\n\nReceived FDA IDE approval for APEX-Return study evaluating AlphaReturn Blood Management System when used with AlphaVac F1885 System\n\n\n\nReceived FDA IDE approval for PAVE clinical study evaluating AngioVac System for treatment of right-sided infective endocarditis\n\n\n\nReceived FDA 510(k) clearance for modified AlphaVac F1885 System with expanded indication for use\n\n\n\nSuccessful conclusion of final outstanding item of previously settled patent litigation with Bard\n\n\n\n*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC, Midline and tip location product portfolios divested in February 2024, as we...